These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Immune complexes in progressive systemic sclerosis and mixed connective tissue disease. Cunningham PH; Andrews BS; Davis JS J Rheumatol; 1980; 7(3):301-8. PubMed ID: 7401065 [TBL] [Abstract][Full Text] [Related]
44. Immune complexes and antibodies to BCG in sera from patients with mycobacterial infections. Carr RI; Chakraborty AK; Brunda MJ; Davidson PT; Damle PB; Hardtke MA; Gilbride KJ; Minden P Clin Exp Immunol; 1980 Mar; 39(3):562-9. PubMed ID: 6991170 [TBL] [Abstract][Full Text] [Related]
45. Physiological aspects of circulating immune complexes in the normal population. Contreras CE; Orozco A; Sánchez P; Ortega G; Bianco NE Clin Exp Immunol; 1982 Jun; 48(3):693-9. PubMed ID: 6981474 [TBL] [Abstract][Full Text] [Related]
46. [Blood levels of immunoglobulins G,A,M, circulating immune complexes, complement and proteins in patients on intermittent peritoneal dialysis]. Majdan M; Ksiazek A; Kozioł M; Szarugiewicz A Pol Tyg Lek; 1989 May 1-8; 44(18-19):415-8. PubMed ID: 2636986 [TBL] [Abstract][Full Text] [Related]
47. Immunoglobulins and complement components in patients with lung cancer. Oner F; Savaş I; Numanoğlu N Tuberk Toraks; 2004; 52(1):19-23. PubMed ID: 15143368 [TBL] [Abstract][Full Text] [Related]
48. The detection of circulating immune complexes in renal transplant patients. Smith MD; Verroust PJ; Griffin PJ; Salaman JR Clin Exp Immunol; 1980 Jan; 39(1):141-5. PubMed ID: 6993064 [TBL] [Abstract][Full Text] [Related]
49. The difference between serum and plasma complement activity in primary renal disease. Akagaki Y; Fujiwara Y; Nakanishi I; Orita Y; Ando A; Abe H; Kitamura H; Nagaki K; Inai S Clin Nephrol; 1980 Aug; 14(2):75-80. PubMed ID: 7408259 [TBL] [Abstract][Full Text] [Related]
51. Complement factors and circulating immune complexes in children with urinary schistosomiasis and asymptomatic malaria. Arinola OG Afr J Med Med Sci; 2005 Mar; 34(1):9-13. PubMed ID: 15971548 [TBL] [Abstract][Full Text] [Related]
52. [Evaluation of serum C3 and CH50 levels as markers of disease-activity and indicators of efficacy of treatment of lupus nephritis in childhood]. Ibe M; Kuriyama T; Mori M; Mitsuda T; Aihara Y; Yokota S Ryumachi; 1994 Aug; 34(4):715-24. PubMed ID: 7974022 [TBL] [Abstract][Full Text] [Related]
53. Circulating immune complexes in Hodgkin's disease. Reactivity of IgG isolated from circulating immune complexes. Nerurkar AV; Advani SH; Gothoskar BP Neoplasma; 1993; 40(2):87-91. PubMed ID: 8350960 [TBL] [Abstract][Full Text] [Related]
54. Late relapse after treatment for clinical stage I and II Hodgkin's disease. Brierley JD; Rathmell AJ; Gospodarowicz MK; Sutcliffe SB; Pintillie M Cancer; 1997 Apr; 79(7):1422-7. PubMed ID: 9083165 [TBL] [Abstract][Full Text] [Related]
56. Demonstration of apoptosis-associated cleavage products of DNA, complement activation products SC5b-9 and C3d/dg, and immune complexes CIC-C3d, CIC-IgA, and CIC-IgG in the urine of patients with membranous glomerulonephritis. Kotnik V; Premzl A; Skoberne M; Malovrh T; Kveder R; Kaplan-Pavlovcic S; Kotnik A; Stiblar-Martincic D Croat Med J; 2003 Dec; 44(6):707-11. PubMed ID: 14652883 [TBL] [Abstract][Full Text] [Related]
57. [Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases]. Tan WY; Hu DS; Zeng FY; Song QB; Hu S; Wei L; Zhou LQ Ai Zheng; 2007 Dec; 26(12):1360-4. PubMed ID: 18076802 [TBL] [Abstract][Full Text] [Related]
58. [Appearance of circulating immune complexes in patients with Hodgkin's disease and the etiology of this disease]. Dziewulska-Bokiniec A; Sztaba-Kania M Wiad Lek; 1992 Oct; 45(19-20):740-3. PubMed ID: 1296377 [TBL] [Abstract][Full Text] [Related]
59. Precipitable immune complexes in Hodgkin's disease. Euler HH; Béress R; Moldenhauer I; Löffler H Int J Cancer; 1983 Oct; 32(4):437-41. PubMed ID: 6618706 [TBL] [Abstract][Full Text] [Related]